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Abstract: Cardiovascular disease remains the most common health problem in developed countries,
and residual risk after implementing all current therapies is still high. Permanent changes in lifestyle
may be hard to achieve and people may not always be motivated enough to make the recommended
modifications. Emerging research has explored the application of natural food-based strategies in
disease management. In recent years, much focus has been placed on the beneficial effects of fish
consumption. Many of the positive effects of fish consumption on dyslipidemia and heart diseases
have been attributed to n-3 polyunsaturated fatty acids (n-3 PUFAs, i.e., EPA and DHA); however,
fish is also an excellent source of protein and, recently, fish protein hydrolysates containing bioactive
peptides have shown promising activities for the prevention/management of cardiovascular disease
and associated health complications. The present review will focus on n-3 PUFAs and bioactive
peptides effects on cardiovascular disease risk factors. Moreover, since considerable controversy
exists regarding the association between n-3 PUFAs and major cardiovascular endpoints, we have
also reviewed the main clinical trials supporting or not this association.
Keywords: cardiovascular disease; clinical trials; cholesterol; fish proteins; hypertension; n-3
polyunsaturated fatty acids; triglycerides
1. Introduction
Cardiovascular disease (CVD) is the most common cause of human morbidity and mortality in
the world, and elevated blood lipids have been strongly associated with increased incidence of CVD.
Expenses for the treatment of CVD to the European health care system are presumed to be as high as
200 billion Euros each year [1]. In the USA, the overall rate of deaths attributed to CVD in 2011 was
229.6 per 100,000 Americans [2]. There are estimates that in 2030, nearly 23.6 million people will die
from CVD worldwide [3]. Due to an aging population and shifting risks posed by the environment,
this burden is expected to increase in developing countries.
Atherosclerosis is the dominant cause of CVD including myocardial infarction, heart failure,
stroke and claudication. Atherosclerosis is mainly located in the intima of middle sized and large
arteries, especially where the vessels divide [4,5]. It is well known that atherosclerosis develops during
a long period of time so the earlier the lipid management is initiated the more likely the atherosclerotic
vascular diseases can be prevented [6].
Lowering low density lipoprotein-cholesterol (LDL-C) is a central target in the prevention of
CVD, especially coronary heart disease. It is estimated that for every 1% reduction in LDL-cholesterol
concentration, there is a corresponding 1% to 2% decrease in the risk of CVD [7–10].
Although genetic factors and aging are important in determining the overall risk, a substantial
proportion of CVD occurs in conjunction with a series of modifiable risk factors, such as hyperlipidemia,
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hypertension, obesity, insulin resistance and diabetes, susceptible to lifestyle modifications, which
include diet and physical exercise [11,12]. Permanent changes in lifestyle may be hard to achieve,
however, and people may not always be motivated enough to make the recommended changes [6].
One solution could be the consumption of foods, which favorably affect the above-mentioned risk
factors, such as nutraceuticals. Nutraceutical is a term coined in 1979 by Stephen DeFelice and defines a
“food, or parts of food, that provide medical or health benefits, including the prevention and treatment
of disease” [13].
With marine species comprising approximately one-half of the global biodiversity, the ocean
offers a wonderful resource for novel compounds, which may serve in improving health of the
worldwide population.
Observational studies first reported in the 1970s showed that the Greenland Inuit populations had
a low incidence of coronary artery disease that was related to their traditional lifestyle and in particular
their distinctive dietary habits, characterized by the consumption of cold-water marine fish and artic
mammals, rich in Ω-3 (or n-3) polyunsaturated fatty acids (PUFAs), particularly eicosapentaenoic
acid (EPA, 20:5 n-3) and docosahexaenoic acid (DHA, 22:6 n-3) [14–16]. Subsequently, researchers
from several prospective epidemiological studies reported that high fish consumption was associated
with a lower mortality from coronary artery disease [17,18]. However, benefits of n-3 PUFAs intake
were challenged by recent clinical trials that failed to replicate protective effects of EPA and DHA
on CVD [19]. It is, therefore, possible that the potential benefit of fish consumption could, in
addition to n-3 PUFAs, be attributed to other nutrients, such as minerals, vitamins and proteins [20].
Fish protein hydrolysates containing bioactive peptides have shown promising activities for the
prevention/management of cardiovascular disease and associated health complications [21].
This review examines current recommendations for fish intake, as source of n-3 PUFAs and
bioactive peptides, and their effects on risk factors for CVD and on specific clinical endpoints.
2. n-3 PUFAs and Cardiovascular Risk Factors
Several data highlighted that n-3 PUFAs are able to affect: lipid profile [22–24], arrhythmia [25],
platelet activity [26,27], endothelial function [28,29], inflammation [30], and blood pressure
(Figure 1) [31].
Mar. Drugs 2016, 14, 113  2 of 15 
 
Although genetic factors and aging are important in determining the overall risk, a substantial 
proportion  of  CVD  occurs  in  conjunction  with  a  series  f  modifiable  risk  factors,  such  as 
hyperlipidemia,  hypertension,  obesity,  insulin  esista ce  a d  dia etes,  susceptibl   to  lifestyle 
modifications, which include diet and physical exercise [11,12]. Permanent changes in lifestyle may 
be  hard  to  achieve,  however,  and  people  may  not  always  be motivated  enough  to  make  the 
recommended changes [6]. One solution could be the consumption of foods, which favorably affect 
the above‐mentioned risk factors, such as nutraceuticals. Nutraceutical is a term coined in 1979 by 
Stephen DeFelice  and defines  a  “food, or parts of  food,  that provide medical or health benefits, 
including the prevention and treatment of disease” [13]. 
With marine species comprising approximately one‐half of  the global biodiversity,  the ocean 
offers  a wonderful  resource  for  novel  compounds, which may  serve  in  improving  health  of  the 
worldwide population. 
Observational studies first reported in the 1970s showed that the Greenland Inuit populations 
had a low incidence of coronary artery disease that was related to their traditional lifestyle and in 
particular their distinctive dietary habits, characterized by the consumption of cold‐water marine fish 
and  artic  mammals,  rich  in  Ω‐3  (or  n‐3)  polyunsaturated  fatty  acids  (PUFAs),  particularly 
eicosapentaenoic acid (EPA, 20:5 n‐3) and docosahexaenoic acid (DHA, 22:6 n‐3) [14–16]. Subsequently, 
researchers from several prospective epidemiological studies reported  that high  fish consumption 
was associated with a lower mortality from coronary artery disease [17,18]. However, benefits of n‐3 
PUFAs intake were challenged by recent clinical trials that failed to replicate protective effects of EPA 
and DHA on CVD [19]. It is, therefore, p ssible that the potential benefit of fish consumption could, 
i  addition to n‐3 PUFAs, be attributed to oth r nutrients, such as minerals, vitamins and proteins 
[20]. Fish protein hydrolysates containing bioactive peptides have shown promising activities for the 
prevention/management of cardiovascular disease and associated health complications [21]. 
This  review examines  current  recommendations  for  fish  intake, as  source of n‐3 PUFAs and 
bioactive peptides, and their effects on risk factors for CVD and on specific clinical endpoints. 
2. n‐3 PUFAs and Cardiovascular Risk Factors 
Several data highlighted that n‐3 PUFAs are able to affect: lipid profile [22–24], arrhythmia [25], 
platelet activity [26,27], endothelial function [28,29], inflammation [30], and blood pressure (Figure 1) [31]. 
 
Figure 1. Beneficial effects of n‐3 PUFAs and peptides from fish on cardiovascular risk factors. n‐3 
PUFAs: n‐3 polyunsaturated fatty acids; TG: triglycerides; TC: total cholesterol; HDL‐C: high density 
lipoprotein‐cholesterol; LDL‐C: low density lipoprotein‐cholesterol. 
Figure 1. Beneficial effects of n-3 PUFAs and peptides from fish on cardiovascular risk factors. n-3
PUFAs: n-3 polyunsaturated fatty acids; TG: triglycerides; TC: total cholesterol; HDL-C: high density
lipoprotein-cholesterol; LDL-C: low density lipoprotein-cholesterol.
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2.1. n-3 PUFAs and Dyslipidemias
Fasting and nonfasting triglycerides (TG) have long been associated with CVD [32]. Fish oils rich
in n-3 PUFAs have well known and long-appreciated TG-lowering properties [33]. Intake of 4 g of
Lovaza [34], a drug formulation containing ethyl ester of EPA (465 mg) and DHA (375 mg), reduce
serum TG by 20%–50%, depending on baseline values [33,35,36].
Recently, the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial, a double-blind,
randomized, controlled investigation of a lipid-altering drug in patients with severe hypertriglyceridemia,
demonstrated that Epanova [37], a novel formulation containing the free fatty acid forms of both EPA
and DHA, significantly lowers TG and non-high density lipoprotein-cholesterol (HDL-C) concentrations
at all the tested doses, i.e., 2, 3, and 4 g/day [36]. Specifically, Epanova at 2-, 3-, and 4-g/day dosages
significantly reduced TG levels from baseline by 25.9%, 25.5%, and 30.9%, respectively, compared with
a 4.3% decline in subjects taking 4 g/day of olive oil. It is important to underline that approximately
84% of the TG reduction at 4 g/day was already present at the 2-g/day dosage [38]. Since it has
been demonstrated that, in individuals on a low-fat diet, bioavailability of EPA + DHA from Epanova
(free fatty acid form of EPA + DHA) is four-fold higher than that from Lovaza (ethyl ester form of
EPA + DHA), the authors hypothesized that the greater bioavailability may have enhanced the efficacy
at lower dosages [38,39]. The explanation of the Epanova’s greater bioavailability may, at least in part,
reside in the fact that, unlike the ethyl ester forms of n-3 PUFA, the free fatty acid form does not require
pancreatic lipase hydrolysis with carboxyl ester lipase, an enzyme which activity is highly dependent on
fat meal content [39]. It can then be speculated that absorption of free fatty acid form of EPA + DHA
would not be compromised by a fat intake restriction and would offer a therapeutic advantage over the
ethyl ester form in patients with severe hypertriglyceridemia.
The mechanisms by which n-3 PUFAs accomplish this hypotriglyceridemic effect have been
explored in kinetic studies in humans [40,41] and animals [42,43], as well as in in vitro and ex vivo
experiments [44]. The majority of the animal studies have been performed in rats and the results, even
though are not always consistent, suggested that at least three mechanisms are responsible for the
hypotriglyceridemic effect: (1) reduced fatty acids availability (due to inhibition of de novo lipogenesis,
decrease of serum levels of nonesterified fatty acids and increase in fatty acid beta-oxidation);
(2) reduced hepatic enzyme activity for TG synthesis; (3) increased phospholipid synthesis and
apoB degradation [33,45,46]. Human studies have shown that n-3 PUFAs exert their effect on TG by
inhibiting hepatic very low density lipoprotein (VLDL) secretion rate and by stimulating serum TG
clearance mechanisms [47–52].
With regard to total cholesterol (TC), HDL-C and LDL-C levels, n-3 PUFAs have little or no effect
on TC, but affect LDL-C and HDL-C concentrations as well as HDL and LDL particle size; these
effects are variable and depend on dose and population studied [53–56]. Moreover, recent evidences
have shown that there are individual differences between EPA and DHA [57]. DHA supplements
increased HDL-C concentrations and LDL particle size [56], whereas a 4 g/day dose of Vascepa [58],
a preparation of EPA as ethyl ester, significantly reduced TC, non-HDL-C and apoB plasma levels in
hypertriglyceridemic patients without raising LDL-C concentrations [59]. Similar effects were observed
in patients with metabolic syndrome [60].
Currently, six n-3 PUFA formulations are approved in the United States to treat adult
people with very high levels of TG (>5.6 mmolL) with or without concomitant elevation of other
atherogenic parameters: omega-3-acid ethyl esters (Lovaza, Omtryg, and 2 generic formulations),
omega-3-carboxylic acids (Epanova), which contain both EPA and DHA, and icosapent ethyl (Vascepa),
which is an EPA-only formulation [61].
2.2. n-3 PUFAs and Arrhythmia
About 80%–90% of sudden cardiac deaths in the early stages after a myocardial infarction
are linked to ventricular arrhythmias, and arrhythmias are associated with electrophysiological
mechanisms controlling muscle contraction [62]. In vitro and animal studies showed that n-3
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PUFAs directly affect cardiac ion channels [62,63]. Data obtained with cardiomyocytes suggested
that n-3 PUFAs exert a marked inhibitory effect on sodium channels, thus reducing excitability,
and a wide range of effects on potassium channels, L-type calcium channels and sodium-calcium
exchanger [62,64–66]. Moreover, n-3 PUFAs have been shown to alter membrane fluidity that could
contribute to effects on ion transport [67,68]. Studies in dogs and in pigs showed that treatment with
n-3 PUFAs reduces ischaemia-induced ventricular fibrillation, by acting on potassium channels [69,70].
Anti-arrhythmic effects of n-3 PUFAs may be mediated in part by their actions on autonomic control,
especially by an increased vagal tone [71]. Altogether these mechanisms would be consistent with
anti-arrhythmic effects and reduction of sudden cardiac death observed in at least some human
studies [17,72–75].
2.3. n-3 PUFAs and Platelet Activity
n-3 PUFAs are considered to have anti-thrombotic effects due to their ability to inhibit
platelet thromboxane A2 synthesis and to act as antagonists of the pro-aggregant thromboxane
A2/prostaglandin H2 receptor [76]. However, these effects have been observed at very high doses
(15 g/day) and for this reason in human trials no consistent effects on platelet aggregation or
coagulation factors were detected [77].
2.4. n-3 PUFAs and Endothelial Function and Inflammation
The mechanism by which n-3 PUFAs influence endothelial function is mediated by their
incorporation into biological membrane phospholipids; this allows modulation of membrane
composition and fluidity [78]. Endothelial cell membrane houses caveolae and lipid rafts where
several receptors and signaling molecules crucial for cell function are concentrated [79]. Caveolae
associated receptor-mediated cellular signal transduction includes important pathways such as the
nitric-oxide (NO) cGMP pathway, the NADPH oxidase and TNF-α-NFκB induced cyclooxygenase-2
and prostaglandin E2 activation pathway [80,81]. By modulating the composition of caveolae, as
described for other lipid classes [82], n-3 PUFAs may exert their beneficial effects, which include
increased NO production and reduced production of pro-inflammatory mediators. Molecular evidence
of enhanced endothelial nitric oxide synthase activity/expression following administration of n-3
PUFAs derives from in vitro and in vivo experimental studies [83,84]. In endothelial cells, n-3 PUFAs
attenuate NF-κB activation, resulting in reduced vascular cell adhesion molecule-1 expression [85,86].
Additionally, n-3 PUFAs exert systemic anti-inflammatory effects by raising the plasma levels of
adiponectin [87] and suppressing the production of interleukin 6, interleukin 1β, soluble E selectin, and
C-reactive protein [65]. Moreover, n-3 PUFAs are precursors of a novel series of lipid mediators (e.g.,
resolvins, protectins, and maresins) with potent anti-inflammatory and pro-resolving properties [88].
2.5. n-3 PUFAs and Blood Pressure
Several studies have indicated that relatively high doses of n-3 PUFAs are able to reduce blood
pressure in both normotensive and hypertensive subjects, even though this effect was more pronounced
in the latest group [31,89–91]. However, in a recent study, Minihane et al. have shown that intakes
of EPA + DHA, achievable through the consumption of 2–3 portions of oily fish/week or 2 fish oil
capsules/day, reduced systolic blood pressure by 5 mm Hg in isolated systolic hypertensive adult
subjects [92]. This effect could be the result of the n-3 PUFAs ability to reduce thromboxane A2
synthesis, increase NO production, and affect the autonomic nerve function [54,93,94].
3. Clinical Trials with n-3 PUFAs: Past and Future
In the Diet and Reinfarction Trial (DART) study, 2033 men after myocardial infarction were
randomly assigned to a group instructed to increase fish intake (corresponding to about 900 mg/day
of EPA + DHA) or to a control group that received no specific information and followed for 2 years.
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The subjects advised to eat fatty fish had a 29% reduction in 2-year all-cause mortality compared with
those not advised [95].
A double-blind, randomized, controlled trial was conducted, in which 205 patients undergoing a
first percutaneous trans-luminal coronary angioplasty (PTCA) received 15 capsules per day containing
1 g of either fish oil (2.7 g/day of EPA and 1.8 g/day of DHA) or olive oil. The treatment was started
3 weeks before PTCA and continued for 6 months thereafter. Restenosis occurred significantly less
often in the fish oil group (22.0%–35.6%) than in the control group (40.0%–53.3%) [96].
The Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione
trial enrolled 11,324 patients with recent myocardial infarction and randomized them to the following
treatment groups: vitamin E (300 mg/day), or EPA and DHA ethyl esters (very similar to Lovaza,
850–882 mg/day) or no supplements (usual care). After 3.5 years of follow-up, the group given n-3
PUFAs experienced a 15% reduction in the primary end point of death, nonfatal myocardial infarction,
and nonfatal stroke (p < 0.02). Moreover, there was a 20% and a 45% reduction in all-cause of mortality
and in sudden death, respectively [73].
The Japanese EPA Lipid Intervention Study (JELIS) investigated the effects of purified EPA for
prevention of major coronary events [97]. A total of 18,645 Japanese individuals with hypercholesterolemia
(TCě 6.5 mmol/L) were randomized to receive 1.8 g/day EPA plus a statin (pravastatin or simvastatin)
or statin only over 5 years. The risk of major coronary events was reduced by 19% in the EPA group
compared with the statin-only group (p = 0.011) and by 53% in the sub-group with TG ě 150 mg/dL
(1.70 mmol/L) and HDL-C < 40 mg/dL (1.04 mmol/L) (HR: 0.47; p = 0.043) [98].
The later GISSI-HF study (N = 7046) demonstrated a small (1.8%), but still significant, reduction
for all-cause mortality in patients with clinical evidence of heart failure (60% of subjects had New York
Class II symptoms, and 40% had previous myocardial infarction) who had been treated with 1 g/day
of n-3 PUFAs in addition to 10 mg/day of rosuvastatin [99].
Patients with chronic heart failure due to nonischemic dilated cardiomyopathy and minimal
symptoms while receiving evidence-based therapy were assessed prospectively by echocardiography
at baseline and at 12 months after randomization to either 2 g of Lovaza or placebo. The main findings
of this study were that 1-year treatment with n-3 PUFAs improves parameters of LV systolic and
diastolic function, as well as functional capacity. However, this study had several limitations, i.e.,
single-center trial, a small sample size and a limited number of clinical events [100].
While these earlier studies on CV outcomes reported favorable effects of n-3 PUFAs, subsequent
clinical trials evaluating the EPA and DHA combination therapy have been disappointing.
A randomized, double-blind, placebo-controlled trial was performed at 6 US medical centers with
enrollment from February 1999 until January 2003. Patients were randomly assigned to receive
fish oil, 1.8 g/day, consisting of 42% EPA and 30% DHA as ethyl esters, or placebo and were
followed up for two years. Among patients with a recent episode of sustained ventricular arrhythmia
and an implantable cardioverter defibrillator, fish oil supplementation does not reduce the risk of
ventricular tachycardia or ventricular fibrillation and may be proarrhythmic in some patients [101].
Three double-blind, randomized intervention studies in patients with implantable cardioverter
defibrillators investigated the direct effects of fish oil on ventricular tachyarrhythmia. None of the
three trials convincingly showed whether or not supplementation with omega-3 PUFA has preventive
effects in these patients [102].
In the randomized, double-blind, placebo-controlled Alpha Omega trial (N = 4837) [100],
patients with previous myocardial infarction, who were receiving state-of-the-art antihypertensive,
antithrombotic, and lipid-modifying therapy, were assigned to use 18.8 g/day of margarine containing
a combination of EPA plus DHA (corresponding to 226 mg of EPA + 150 mg of DHA) or placebo for
40 months. At the end of the study, there were no statistically significant differences in the incidence of
total fatal or nonfatal CV events between the two groups. However, in this trial the beneficial effects of
low-dose EPA plus DHA therapy may have been difficult to prove because the patients were receiving
state-of-the-art clinical care [103].
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In the OMEGA trial, patients with acute myocardial infarction (N = 3851) received 1-g capsules
containing either 460 mg EPA and 380 mg DHA or placebo daily in addition to guideline-adjusted
therapy and were followed for 1 year [101]. Rates for the primary efficacy outcome of sudden cardiac
death were 1.5% in both study arms (p = 0.84) Differences in secondary end points such as major CV or
cerebrovascular events were also statistically similar. Interpretation of the results from the OMEGA
trial was limited because the study lacked sufficient statistical power. The sample size and event rates
used in the OMEGA study were based on prior studies, but the patient population was receiving
considerably improved guideline-adjusted treatment of acute myocardial infarction, and thus the
number of sudden death events was lower than expected [104].
Similar results were obtained in the Supplémentation en Folates et Omega-3 (SU.FOL.OM3)
clinical study. This study does not support the use of dietary supplements containing n-3 PUFAs
(600 mg of EPA and DHA at a ratio of 2:1) for prevention of cardiovascular disease in people with a
history of ischaemic heart disease or ischaemic stroke [105].
The effects of long-term treatment with Lovaza (1 capsule/day) on CV events was examined in the
Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial in patients with type 2 diabetes
mellitus, impaired fasting glucose, or impaired glucose tolerance (N = 12,536). The study found that
1 g/day of EPA/DHA did not prevent death or any CV outcomes in this patient population [106].
In the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) trial,
the effects of perioperative n-3 PUFA supplementation (Lovaza) on the occurrence of postoperative
atrial fibrillation was assessed in patients who underwent cardiac surgery (N = 1516). No significant
difference was observed between patients who received the perioperative n-3 PUFA supplementation
and those who received placebo [107].
With the aim of assessing the role of n-3 PUFAs supplementation on CVD, several meta-analyses
have been published, but the conclusions are not straightforward. Two recent meta-analyses published
in the same year for example ended with different conclusions: one stated that n-3 PUFAs are not
universally associated with major CV outcomes across patient populations at increased cardiovascular
risk [108]; the second indicated that marine n-3 PUFAs, when administrated as food or as supplements
for at least six months, reduce CV events by 10%, cardiac death by 9% and coronary events by 18%,
while showing a trend toward a lower total mortality [109].
In conclusion, further studies are needed to assess the efficacy of n-3 PUFAs therapies in the
context of current standards of clinical care, in sufficiently large patient populations and at higher
doses. The ongoing, prospective, randomized, double-blind Reduction in Cardiovascular Events with
EPA-Intervention Trial (REDUCE-IT; NCT01492361) will assess the ability of Vascepa to reduce CV
outcomes in high-risk statin-treated patients with hypertriglyceridemia. Moreover, the VITAL study,
an ongoing (NCT01169259) placebo-controlled trial powered to examine major cardiovascular events,
as well as CVD and stroke individually, may clarify the utility of n-3 PUFAs (Lovaza) in primary
prevention of CVD [110].
4. Fish Proteins and Cardiovascular Risk Factors
Numerous studies, briefly reviewed here below, have demonstrated beneficial effects of fish
proteins and fish-derived peptides on CV risk factors, such as lipid disorders and hypertension
(Figure 1).
4.1. Fish Proteins and Dyslipidemias
In animal studies, proteins from different fish species have been shown to display
hypocholesterolemic activity when compared with casein as protein source [111]. The exact
mechanisms responsible for the hypocholesterolemic effect of fish proteins have not been fully
identified. The amino acid composition of dietary proteins probably influences plasma cholesterol
levels. On this respect, dietary proteins with a low ratio of methionine-glycine and lysine-arginine, such
as fish proteins, seem to favor a hypocholesterolemic effect [112,113], in contrast with bovine casein,
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which tends to elevate cholesterol levels and is characterized by a high ratio of methionine-glycine
and lysine-arginine [114]. Mechanistic explanations for the hypocholesterolemic effect of fish proteins
include increased hepatic LDL receptor expression [115,116]. Additionally, administration of fish
protein hydrolysate to rats, led to an increased hepatic cholesterol 7α-hydroxylase expression and
higher cholesterol and bile acids fecal content compared with casein-fed animals [117]. In this study,
a hypotriglyceridemic effect by fish protein hydrolysate was also observed.
Among the few clinical studies evaluating the hypocholesterolemic effect of fish proteins,
consumption of a cod-fish protein supplement by overweight adults had no effect on triglycerides or
HDL-cholesterol levels, but significantly decreased serum LDL-cholesterol levels from baseline [118].
Further studies are needed on larger cohorts and for longer time spans, to confirm the hypocholesterolemic
effect of fish protein intake.
4.2. Fish Proteins and Hypertension
The antihypertensive activity of peptides from different food sources has been demonstrated
both in experimental models and in human volunteers [119]. The discovery of antihypertensive
peptides from marine organisms started in the early 1990s, when “Katsuobushi”, a Japanese seasoning
prepared from bonito, a fish from tuna family, was examined for its potential to inhibit the activity of
angiotensin-converting enzyme (ACE). Fujita et al. [120] developed a thermolysin hydrolysate from
“Katsuobushi”. This hydrolysate was administered, in fermented drinking water with vinegar, to
normotensive human subjects and to patients with mild or moderate hypertension in a small-scale
clinical trial. The hydrolysate contained the previously described ACE inhibitory peptide LKPNM [121].
A significant decrease of both systolic and diastolic blood pressure was reported [122].
ACE inhibitory peptides have been found in various other fish species, [123]. Among those,
a dipeptide from sardine muscle hydrolysate exhibited antihypertensive effect on mild hypertensive
subjects [124]. This same dipeptide was also shown to induce vasodilation thorough a moderate
blocking activity on voltage-operated Ca2+ channels [125]. Potent ACE inhibitory peptides derived
from salmon were also found to possess strong antihypertensive effect in spontaneously hypertensive
rats (SHR) [126]. Among 8 proline-containing ACE inhibitory dipeptides isolated from fermented
anchovy sauce, KP could significantly lower the blood pressure of SHR [127].
Subsequently, there has been growing interest in exploring the possible uses of the fish by-products
or the remaining raw materials, so that they can potentially be utilized rather than posing a waste
and sustainability problem [128]. As examples, ACE inhibitory peptides have been produced
from sea brame scales [129] and Alaskan Pollack skin [130]. Anti-hypertensive peptides were also
found in pepsin digests of bonito pyloric appendix. Those peptides, in vitro, inhibited by 40% the
endothelin-converting enzyme activity, thus potentially reducing endothelin-1 production [131].
Fish-derived bioactive peptides have enormous potential and have been utilized in the production
of pharmaceutical products with an active functional role and effect on health; for example, blood
pressure lowering capsules have been manufactured that contain Katsuobushi Oligopeptide LKPNM
which is converted into its active form (LKP) by digestive enzymes (Vasotensin 120TTM by Metagenics,
Aliso Viejo, CA, USA; PeptACETM Peptides 90 by Natural Factors, Monroe, WA, USA) [132].
4.3. Fish Proteins and Other Potential Anti-Atherosclerotic Effects
Fish protein peptides and hydrolysates have been found to exert antioxidant effects, extensively
reviewed in two recent papers [133,134].
Dietary cod proteins were shown to improve insulin sensitivity in insulin-resistant patients [135].
Recently, dietary intake of a salmon peptide fraction prevented glucose intolerance, dyslipidemia, and
adipose tissue inflammation in obese mice fed a high-fat, high-sucrose diet [136]. These results suggest
that fish peptide supplementation may contribute to the prevention of metabolic syndrome and reduce
type 2 diabetes and cardiovascular risk.
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In a recent study, apolipoprotein E deficient mice were fed for 12 weeks a high fat diet containing
21% w/w casein as protein source (control), or the same diet except for 5% w/w salmon protein
hydrolysate replacing the same amount of casein (SPH) [137]. A significant reduction of atherosclerosis
development was observed at the aortic sinus of mice fed SPH compared to controls (Figure 2A).
Interestingly, this effect was not accompanied by differences in plasma lipid levels between the two
groups, but a significant reduction of circulating pro-inflammatory cytokines was observed in SPH fed
mice (Figure 2B), suggesting that salmon protein hydrolysate may reduce atherosclerotic development,
at least in part, also by inhibiting activation of systemic inflammation.
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5. Conclusions
Based on several studies reporting a lower CVD mortality in regular fish consumers, guidelines
for healthy individuals encourage the consumption of fish, preferably oily types, at least twice a week.
The beneficial effects of fish could be attributed to a wide array of nutrients, particularly n-3 PUFAs and
proteins/peptides, which display several beneficial effects on the cardiovascular system. The benefit of
the isolated nutrients on primary and secondary prevention of CVD has still to be confirmed/proven
in further clinical studies.
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